Sparrow Pharmaceuticals Announces Phase 2a Data Showing Cardiometabolic Benefits of Clofutriben in Adults with Type 2 Diabetes

Clofutriben improved HbA1c and other cardiometabolic parameters in patients with Type 2 diabetes in a 6-week, placebo-controlled, randomized Phase 2 trial Subset of participants with elevated cortisol (EC) risk factors showed numerically greater improvements in glycemic control and lipid parameters, along with benefits on blood pressure and body weight

The release as fetched from its publisher. sparrowpharma.com ↗